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Background: Recent explorative studies suggest that propranolol reduces retinopathy
of prematurity (ROP) progression, but the short-term effects of propranolol treatment at
1 year of corrected age have not been extensively evaluated.
Methods: A multi-center retrospective observational cohort study was conducted to
assess the physical development and the refractive outcome of infants with prior ROP
treated with propranolol. Forty-nine infants treated with propranolol were compared with
an equal number of patients who did not receive any propranolol therapy and represent
the control group, with comparable anthropometrical characteristics and stages of ROP.
Results: The weight, length, and head circumference at 1 year of corrected age
were similar between infants who had been treated, or not, with propranolol, without
any statistically significant differences. Refractive evaluation at 1 year showed spherical
equivalent values decreasing with the progression of ROP toward more severe stages
of the disease, together with an increasing number of infants with severe myopia. On
the contrary, no differences were observed between infants who had been treated with
propranolol and those who had not.
Conclusion: This study confirms that the progression of ROP induces an increase
of refractive errors and suggests that propranolol itself does not affect the refractive
outcome. Therefore, if the efficacy of propranolol in counteracting ROP progression is
confirmed by further clinical trials, the conclusion will be that propranolol might indirectly
improve the visual outcome, reducing the progression of ROP.
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INTRODUCTION
Despite continuous progress in the clinical management of
prematurely born newborns, Retinopathy of prematurity (ROP)
remains an important cause of potentially avoidable visual
impairment and blindness in children (1, 2). Prematurity, low
birth weight and premature oxygen exposition are the main risk
factors associated with ROP (3). While other factors such as
sepsis, intraventricular hemorrhage, and necrotizing enterocolitis
may play a role in ROP development (3), the duration and the
entity of oxygen exposition represents the main factor involved
in its development (4).
Even though the pathogenesis of ROP has not been completely
clarified yet, it appears as an oxygen-dependent biphasic disease,
where two specular phases are clearly detectable (5). The
first phase follows the oxygen extrauterine exposure and is
characterized by the down-regulation of retinal pro-angiogenic
factors, such as Vascular Endothelial Growth Factor (VEGF) and
Insulin-like Growth Factor 1 (IGF-1). This event induces growth
arrest, or even regression, of the normal retinal vasculature
(“avascular” or “ischemic” phase). However, this phase promotes
the transition to the following hypoxic phase. In fact, the
increasedmetabolic demands of the maturing retina conflict with
the rudimentary vascularisation, inducing progressive hypoxia
that, in turn, causes a localized up-regulation of proangiogenic
factors. This second phase of ROP, apparently specular to the
previous phase, is characterized by a diffuse vaso-proliferation
and retinal neovascularization, and is therefore usually called
“proliferative.” These two phases are strictly related to each
other, because the entity of the vascular obliteration during the
first ischemic phase affects the degree and severity of retinal
hypoxia in the following phase, inducing the up-regulation of
retinal VEGF and consequently the neovascularization. These
new vessels can grow out from the retina into the vitreous,
inducing retinal edema and hemorrhage because of the increased
permeability of these abnormal new vessels. This process can
induce the formation of an abnormal fibrovascular tissue that
can produce traction on the retina, which may lead to retinal
distortion or detachment (5, 6).
Beyond the risk of retinal detachment, infants with prior ROP
are at increased risk of developing visual impairment, related to
refractive errors such as severe myopia and strabismus (7, 8). For
this reason, the detection of effective therapeutic strategies is a
question of global interest.
The ablation of the peripheral retina with laser
photocoagulation is the most commonly used treatment
and has been considered as the gold standard of ROP treatment:
laser burns destroy the full thickness of the peripheral retina,
which prevents neovascularization, reducing the progression of
the disease. However, the visual outcome after treatment is still
poor, especially for zone I ROP (9). Additionally, laser treatment
can induce some adverse effects such as loss of the visual field,
Abbreviations: ROP, retinopathy of prematurity; VEGF, vascular endothelial
growth factor; IGF-1, insulin growth factor-1; β-AR, β-adrenoreceptor; NICU,
neonatal intensive care unit; SE, spherical equivalents; D, diopters; TG, treated
group; CG, control group.
high myopia, corneal edema, intraocular hemorrhage, cataract
formation, intraocular pressure changes (10). An alternative
treatment currently available is represented by the intravitreal
injection of neutralizing anti-VEGF antibodies. This treatment
avoids retinal destruction but is not free from complications
and systemic or local adverse events. Moreover, neither short-
nor long-term data regarding their safety profile are currently
available. Therefore, further studies are needed to evaluate their
effects on functional and neurodevelopmental outcomes (11).
A recent meta-analysis suggests that laser photocoagulation is
probably more efficient than VEGF antagonists (less retreatment
incidence) but induces more eye complications and increased
myopia (12), even though this aspect is still controversial among
specialists (13). Therefore, there is an urgent need for new
pharmacological approaches in the prevention and treatment
of ROP.
In the last few years, propranolol, a non-selective β1- and
β2-adrenoreceptor (β-AR) blocker, has become an emerging
option for treatment of ROP. Propranolol is currently considered
as the first-line therapy of choice for the treatment of infantile
hemangiomas (14), thanks to its ability to suppress the
production of pro-angiogenic factors (15, 16). Considering
the numerous pathogenetic analogies between infantile
hemangiomas and ROP (17), pre-clinical (18–21), and clinical
studies have explored the safety and efficacy of propranolol
in reducing ROP progression. Oral propranolol resulted in
being effective in limiting ROP progression (22–25); however,
it was not considered safe enough to recommend for use in
preterm infants due to the high incidence of life-threatening
events observed in newborns taking 1 or 2 mg/kg/day of
propranolol (22). This observation suggested to explore the
feasibility of a topical approach to ensure an appropriate retinal
propranolol delivery. A preliminary study performed in mice
with oxygen-induced retinopathy (OIR), a well-established
model of ROP, demonstrated that topical propranolol had an
efficacy comparable to that of subcutaneous or oral propranolol
(26). Subsequently, in rabbits, we demonstrated that the
administration of one drop of 25 µL of 0.1% propranolol
applied to both eyes every 6 h for 5 consecutive days produced
retinal concentrations similar to, but plasma concentrations
significantly lower than those measured after 1 mg/kg/day
oral administration (27). These studies suggested that topical
eye application can constitute an alternative delivery route
to systemic administration also in newborns, in order to
avoid the risk of associated side effects. A first clinical trial
performed in newborns with stage 2 ROP demonstrated that
propranolol 0.1% eye micro-drops were well-tolerated, but not
sufficiently effective (28). On the contrary, a second clinical trial
demonstrated that propranolol eye micro-drops administered a
higher concentration (0.2%) and started at an earlier stage of the
disease (stage 1 ROP) reduced ROP progression and showed an
excellent safety profile (29).
However, the short-term effects of propranolol treatment at
1 year of corrected age have not been extensively evaluated.
In the animal model, propranolol treatment recovered visual
dysfunction induced by oxygen exposure, restoring retinal
function, as demonstrated by electroretinogram recordings (21).
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In humans, a recent clinical study showed a poorer refractive
status at 1 year of age, in infants previously treated with
propranolol (30).
The aim of the present study was to investigate whether
propranolol administration in preterm infants with ROP,
regardless of its ability to counteract the progression of the
ROP, affects refractive status at 1 year of age in former
preterm infants.
METHODS
This is a retrospective observational cohort study that included
patients with ROP admitted to the Neonatal Intensive Care
Unit (NICU) of the Meyer University Children’s Hospital in
Florence, and Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico inMilan, Italy. The study assessed the refractive status
of former premature infants with previous ROP treated with
propranolol (oral or topic) vs. infants with comparable stages of
ROP who had not been treated with propranolol. We evaluated
physical development parameters and refractive status at 1 year of
corrected age. The study was approved by the institutional ethics
committee, and informed consent was obtained from both the
parents of all patients.
Newborns admitted to the two NICUs in the period 2010–
2017, and treated with propranolol were eligible, but only
infants with anthropometrical and ophthalmologic follow-up
at 1 year of corrected age (standard of care for all infants
with ROP) were included. We matched cases, those who
had received oral or topic propranolol treatment, with an
equal number of patients admitted in the same period who
did not receive any propranolol therapy and represent the
control group, with comparable characteristics in terms of
stages of ROP, birth weight and gestational age. Newborns
treated with oral propranolol were treated with 1 or 2
mg/Kg/day and were enrolled with ROP stage 2 (22). While
newborns treated with propranolol eye micro-drops at 0.1%
were enrolled with ROP stage 2 (28), those treated with eye
micro-drops at 0.2% were enrolled with ROP stage 1 (29).
Patients who developed a severe grade of ROP (stage 2 plus
or 3 plus) were treated with laser or anti-VEGF antibodies
according to the ophthalmologist, regardless of any prior
treatment with propranolol. An experienced ophthalmologist
specialized in ROP and blinded to the intervention evaluated
the patients during hospitalization and then during the
follow-up. They recorded the progression and severity of
the disease according to International classification (31).
The anthropometric (weight, height, head circumference) and
ophthalmologic follow-up was performed at 1 year of corrected
age. Refractive status was evaluated through a cycloplegic
retinoscopy with 1% tropicamide. Spherical equivalents (SE)
were determined through skiascopy or handheld autorefractor
(Retinomax 3, Nikon Inc., Japan) and measured in diopters
(D). Myopia, defined as a SE <0 D, was distinct in mild
myopia (0 to −1.5 D), moderate myopia (−1.5 to −6D), and
high myopia (> −6 D) (32). Hypermetropia was considered
significant if <+3 D.
Statistical Analysis
To estimate the sample size, we used a web calculator (Sealed
Envelope Ltd. 2012). Assuming an α error of 5%, a power value
of 80%, a standard deviation of outcome of 1.09 (33) and a
non-inferiority limit of 0.6, 82 patients had to be enrolled.
The data were analyzed by using the SPSS 25.0 (SPSS
Inc. Chicago, Illinois) statistical package program. Continuous
variables are presented as means ± standard deviations and
95% confidence intervals were determined. Nominal variables
were presented as numbers and percentages. Comparisons
between the approaches were performed with Student’s t-test
and one-way ANOVA for continuous variables and Chi-squared
or Fisher’s exact test for categorical data. The groups with
significant differences compared to continuous variables were
post-hoc analyzed. The post-hoc analysis was performed using
one-way ANOVA test with least significant difference (LSD) and
Bonferroni methods. A p < 0.05 was accepted as statistically
significant. The difference in incidence of refractive errors
between treated or control groups was evaluated by means of the
odds ratio (OR).
RESULTS
Among the 85 eligible newborns (the newborns enrolled in the
different clinical trials in the two NICUs involved in the study),
36 were excluded, 5 because they died, and 31 because they were
lost at follow-up (Figure 1). The infants lost to follow-up showed
baseline data comparable to those of newborns monitored at
follow-up (GA 191.5 ± 15.0 days, Birth weight 811 ± 260 g, 10
with stage 1 ROP, 13 with stage 2, 9 with stage 3, and 4 with stage
2 or 3 plus).
The 49 patients enrolled who received propranolol therapy
(Treated Group, TG) were matched with 49 patients with
equivalent anthropometrical parameters and comparable stages
of disease who did not receive any pharmacological treatment
and representing the Control Group (CG). Among all newborns
of the TG, 19 patients were treated with oral propranolol (4 with
0.25 mg/kg/6 h and 15 with 0.5 mg/kg/6 h, for a mean of 66± 30
days), 10 were treated with eye micro-drops at 0.1% (three micro-
drops every 8 h in both eyes, for a mean of 60 ± 17 days), and
20 patients received eye micro-drops at 0.2% (three micro-drops
every 6 h in both eyes, for a mean of 70± 27 days).
Baseline characteristics and anthropometric measurements
are described in Table 1. The TG and the CG showed comparable
gestational age, weight, length, and head circumference at birth.
We found no significant differences in disease progression
measured in terms of maximum stages of ROP reached
(Table 1). The number of patients who required more invasive
treatment (laser phototherapy or anti-VEGF administration)
was comparable between the groups, without any significant
difference even though the trend toward a reduced progression
in TG was evident.
Weight, length, head circumference, and refractive status were
measured at similar corrected ages (10.6 ± 2.1 months of post-
menstrual age in the TG, 11.3± 1.7months of post-menstrual age
in the CG; p = 0.069). The anthropometric parameters (weight,
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FIGURE 1 | Flow chart illustrating patient enrollment of this retrospective observational cohort study.
TABLE 1 | Baseline characteristics and anthropometric measurements at birth.
Treated group Control group p
Infants, n 49 49
GA, days, mean ± DS 184.8 ± 16.0 189.0 ± 18.4 0.228
Birth weight, grams,
mean ± DS
804 ± 197 891 ± 288 0.083
Birth head
circumference, cm,
mean ± DS
23.5 ± 2.6 24.4 ± 2.6 0.091
Birth length, cm, mean
± DS
33.8 ± 3.7 34.8 ± 2.7 0.121
ROP Stage 1, n (%) 10 (20.4%) 18 (36.7%) 0.075
ROP Stage 2, n (%) 20 (40.8%) 15 (30.6%) 0.297
ROP Stage 3, n (%) 12 (24.5%) 5 (10.2%) 0.063
ROP Stage 2 or 3 plus,
n (%)
7 (14.3%) 11 (22.4%) 0.302
Treated with invasive
therapy (anti VEGF or
laser), n (%)
7 (14.3%) 11 (22.4%) 0.302
length, and head circumference) at 1 year of corrected age
were similar between the groups, without statistically significant
differences (Table 2). Refractive evaluation at 1 year showed SE
values decreasing with ROP progression. In infants with prior
ROP stage 2–3 plus who had undergone invasive treatment, the
TABLE 2 | Anthropometric measurements at 1 year of post-menstrual age.
Treated group Control group p
Infants, n 49 49
Weight at 1 year,
grams, mean ± DS
7,820 ± 1,100 7,855 ± 1,035 0.871
Length at 1 year, cm,
mean ± DS
70.5 ± 4.9 71.1 ± 5.0 0.542
Head circumference at
1 year, cm, mean ± DS
44.0 ± 2.0 43.8 ± 1.3 0.628
value of SE was significantly lower if compared with infants
with prior stage 1, 2, or 3 ROP (Figure 2). The poorer refractive
outcome of infants with previous ROP stage 2–3 plus who had
undergone invasive treatment is confirmed by the higher number
of severe myopia observed in this group (Table 3). Infants with
prior stage 2–3 plus ROP show a risk to develop a severe myopia
significantly higher than newborns with ROP stages 1–3 (OR
30.385; 95% CI 3.281–281.380; p= 0.0026).
Refractive evaluation at 1 year showed a SE in the infants
of TG similar to those observed in the CG. Also comparing
the SE measured in infants (treated or not with propranolol)
at the same stage of severity of the disease, no differences in
the refractive outcome were observed (Figure 3). The similar
refractive outcome of infants treated, or not, with propranolol is
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FIGURE 2 | Mean spherical equivalents at 1 year of post-menstrual age in Left or Right Eye in correlation with ROP stages. Vertical lines indicate 95% confidence
intervals.
TABLE 3 | Number of patients with refractive errors correlated with the stages of ROP.
n Mild myopia Moderate myopia High myopia Hypermetropia
Stage 1 ROP 28 2 (7.1%) 0 (0) 0 (0) 4 (14.3%)
Stage 2 ROP 35 7 (20.0%) 7 (20.0%) 1 (2.8%) 4 (11.4%)
Stage 3 ROP 17 3 (17.6%) 2 (11.8%) 0 (0) 2 (11.8%)
Stage 2–3 plus ROP 18 4 (22.2%) 3 (16.7%) 5 (27.8%) 3 (16.7%)
FIGURE 3 | Mean spherical equivalents at 1 year of post-menstrual age in Left or Right Eye in correlation with treatment or not with propranolol. Vertical lines indicate
95% confidence intervals.
demonstrated by the similar distribution of refractive errors in
these two groups (Table 4).
No statistically significant differences of SE were observed
among infants without any pharmacological treatment and
infants treated with oral propranolol, or eye micro-drops at 0.1,
or at 0.2% (Table 5).
DISCUSSION
The possible efficacy of propranolol (oral or topical) in reducing
the progression of ROP, on the one hand opens up high
hopes for an effective and economical treatment, but on
the other hand raises questions about the short- and long-
term effects of propranolol treatment. This study reports the
anthropometric and refractive outcome at 1 year of post-
menstrual age in a series of infants with different stages of
ROP, treated or not with propranolol, to obtain information
about the possible effect of propranolol in the short-term
refractive outcome.
Regarding physical growth, that was comparable between both
groups at birth, no difference of anthropometric parameters
was observed at 1 year of age between the group that received
propranolol and the CG, confirming the data already reported for
infants treated with propranolol for infantile hemangiomas (34).
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TABLE 4 | Number of patients with refractive errors correlated with the treatment or not with propranolol.
Treated group Control group OR (95% CI) p
Infants, n 49 49
Mild myopia, n 10 (20.4%) 6 (12.2%) 1.838 (0.611–5.526) 0.279
Moderate myopia, n 7 (14.3%) 5 (10.2%) 1.467 (0.432–4.983) 0.614
High myopia, n 2 (4.1%) 4 (8.2%) 0.479 (0.083–2.744) 0.408
Hypermetropia, n 7 (14.3%) 6 (12.2%) 1.194 (0.371–3.850) 0.766
TABLE 5 | Refractive evaluation at 1 year of post-menstrual age in newborns with different treatments.
Control group Oral propranolol Propranolol eye
micro-drops
0.1%
Propranolol eye
micro-drops
0.2%
p
Infants, n 49 19 10 20
SE LE, D (mean ± DS) +0.25 ± 3.74 +0.47 ± 3.35 +1.08 ± 1.51 +0.93 ± 1.78 NS
SE RE, D (mean ± DS) +0.53 ± 3.57 +0.47 ± 3.23 +0.98 ± 1.42 +0.37 ± 2.71 NS
SE, Spheric equivalent; LE, Left Eye; RE, Right Eye.
Results of the refractory outcome show values of the SE in line
with data of the literature (35) and suggest that, at the same stage
of ROP, propranolol itself doesn’t affect the refractive outcome.
In fact, the number of infants with refractive errors were similar
in both the TG and the CG. Results shown in Table 5 indicate
that among infants treated with propranolol, mild myopia prevail
compared to infants in the control group, while severe myopia
seem to be less frequent. However, these data do not reach
statistical significance and therefore deserve to be confirmed by
more extensive studies. On the contrary, the refractive outcome
worsens with the progression of the severity of the ROP, as
demonstrated by the high percentage of severe myopia in infants
who had undergone invasive procedures, demonstrating that
the progression of ROP affects the refractive outcome. This
observation is based on a small number of infants, but results are
in agreement with previous literature findings (36, 37).
These observations suggest that while propranolol itself does
not affect the refractive outcome, the progression of ROPworsens
the refractive defects. If these data are confirmed by further
study, and if the efficacy of propranolol in counteracting ROP
progression is confirmed by further clinical trials, the conclusion
will be that propranolol might indirectly improve the visual
outcome simply by reducing the progression of ROP.
The results of this study are in apparent contrast with
the study of Korkmaz et al., where the authors reported a
poorer refractive outcome in newborns treated with propranolol
(27–30). It is difficult to provide a specific explanation for
this discrepancy. In all the studies, the number of the
enrolled infants was small, the route and the dosage of
propranolol administration was not homogeneous, and therefore
only theoretical speculations are possible. However, the trial
performed by Korkmaz et al. differed from those performed in
our centers, mainly regarding the moment in which propranolol
treatment was started. While all the patients enrolled in our
studies were treated with propranolol during the proliferative
phase of ROP (during stage 1 or 2 ROP), in the study of
Korkmaz, newborns were treated on the basis of their gestational
and post-conceptional age. Newborns born before 27 weeks of
gestational age started oral propranolol at 32 post-menstrual
weeks, those born at 27–29 weeks started propranolol at 33
post-menstrual weeks, and, finally, newborns born at 30 or later
gestational weeks, received propranolol at 34 post-menstrual
weeks. The consequence of this approach was that, in the study
of Korkmaz, 30 newborns were treated with propranolol before
ROP appearance, during the ischemic phase, and 53 newborns
during the proliferative phase (24, 25). The study that explored
the visual outcome of these newborns analyzed 34 of the 83
newborns treated with propranolol, but unfortunately, in this
article, it was not reported how many of these patients started
treatment during the proliferative phase or the ischemic phase.
Recently, we have demonstrated that the phase in which
propranolol is started affects its effectiveness. In fact, propranolol
administered during the proliferative phase has a protective
effect, with an evident reduction in ROP progression, while
the administration of propranolol during the ischemic phase
exerts a probable deleterious effect (26–29). This apparently
contradictory effect is definitely explainable by the bi-phasic and
specular nature of ROP. It is, in fact, easy to understand that
the administration of propranolol, a molecule able to reduce the
production of VEGF, may be useful during the proliferative phase
of ROP, when VEGF is dramatically increased, and a reduction
of VEGF is desirable, but detrimental if administered during the
ischemic phase, when levels of VEGF are too low to permit a
normal vascularization of the retina, and an increase of VEGF is
suitable. In light of these results, we speculated that propranolol
is only useful during the proliferative phase of ROP (26–29).
In conclusion, we cannot exclude that the discrepancy of the
results between these two studies may be related to the different
strategy adopted.
This study has some evident limitations which have to
be pointed out. The most important flaws of this study
are the retrospective design, the small number of patients
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analyzed, and the low follow-up rate (58%) of propranolol-
treated infants, due to the fact that many infants were
followed in centers closer to their cities of residence. The
populations compared were not perfectly homogeneous: in
the CG the number of infants who developed stage 2–3
plus was greater than in the TG. Even if this difference
has not reached the statistical significance, we cannot exclude
that this lack of homogeneity has conditioned the results of
the refractive outcome. Moreover, although all the patients
treated with propranolol received this treatment during the
proliferative phase, the route of administration and the dose
were markedly different, with different plasma concentration.
Finally, the visual follow-up was restricted to a first year
of post-menstrual age. Therefore, further studies, possibly
prospective placebo-controlled trials, with a larger sample size are
urgently warranted.
CONCLUSION
In conclusion, this study suggests that propranolol administered
during the proliferative phase of ROP does not affect the
refractive outcome, while the progression of ROP does. If
further studies confirm that propranolol can counteract ROP
progression, it will be possible to conclude that propranolol
indirectly improves the visual outcome.
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